What is Trintellix (Vortioxetine)?
Trintellix (vortioxetine) is an FDA-approved antidepressant indicated specifically for the treatment of major depressive disorder (MDD) in adults. 1
Mechanism of Action
Vortioxetine is classified as a serotonin modulator and stimulator with a unique multimodal mechanism of action that distinguishes it from traditional SSRIs and SNRIs. It functions through:
- Serotonin transporter (SERT) inhibition - blocks serotonin reuptake
- 5-HT3 and 5-HT7 receptor antagonism - blocks these receptor subtypes
- 5-HT1A receptor agonism - activates this receptor
- Additional effects on 5-HT1B and 5-HT1D receptors
This multimodal activity affects not only serotonin but also modulates glutamate, GABA, norepinephrine, acetylcholine, and dopamine neurotransmission 2, 3.
FDA-Approved Indication
Major Depressive Disorder in adults - This is the sole FDA-approved indication 1.
Dosing Recommendations
Starting dose: 10 mg orally once daily without regard to meals 1
Target dose: Increase to 20 mg daily as tolerated 1
Lower dose option: 5 mg daily for patients who cannot tolerate higher doses 1
Maximum dose: 20 mg daily (standard patients); 10 mg daily in known CYP2D6 poor metabolizers 1
Dose Adjustments
- With strong CYP2D6 inhibitors (e.g., bupropion): Reduce dose by half 1
- With strong CYP inducers (e.g., rifampin): Consider increasing dose up to 3 times the original dose when co-administered for >14 days 1
Discontinuation
Vortioxetine can be stopped abruptly, but for doses of 15-20 mg daily, taper to 10 mg daily for one week before full discontinuation if possible 1.
Clinical Efficacy
Recent meta-analyses demonstrate vortioxetine's effectiveness in acute MDD:
- Response rate: 53.2% (vs. placebo 35.2%)
- Remission rate: 29.2% (vs. placebo 19.3%)
- Dose-response relationship: 20 mg daily shows greater effect size than 10 mg daily 4
Notably, vortioxetine demonstrates particular efficacy in patients with MDD and high anxiety symptoms 5, and shows superiority over agomelatine in patients who failed initial SSRI/SNRI therapy 6, 7.
A distinctive feature is vortioxetine's positive effects on cognitive symptoms (memory, executive function) in MDD patients, which may exceed standard antidepressants 2, 8.
Contraindications
Absolute contraindications:
- Hypersensitivity to vortioxetine or formulation components 1
- Concurrent use with MAOIs or within 21 days of stopping vortioxetine 1
- Starting vortioxetine within 14 days of stopping an MAOI 1
- Concurrent use with linezolid or IV methylene blue 1
Warnings and Precautions
Black Box Warning
Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients - Close monitoring required, especially during the first 1-2 months of treatment 1, 9. Vortioxetine is NOT approved for pediatric use 1.
Serious Risks
- Serotonin syndrome: Risk increases with co-administration of other serotonergic agents; discontinue immediately if occurs 1
- Bleeding risk: Increased with concurrent NSAIDs, aspirin, antiplatelet drugs, or anticoagulants 1
- Activation of mania/hypomania: Screen for bipolar disorder before initiating 1
- Angle-closure glaucoma: Can occur in patients with untreated anatomically narrow angles 1
- Hyponatremia/SIADH: Monitor for symptoms 1
- Sexual dysfunction: May occur with treatment 1
- Hepatotoxicity: Rare but documented cases of drug-induced hepatitis exist 10
Adverse Effects
Most common (≥5% and twice placebo rate):
- Nausea (most frequent)
- Constipation
- Vomiting 1
The nausea can be mitigated by starting at 30 mg daily for one week before increasing to target dose, though this applies more to duloxetine dosing strategies 11.
Pharmacokinetics
- Bioavailability: 75%
- Half-life: ~66 hours
- Time to steady state: ~2 weeks
- Dosing frequency: Once daily
- Food effect: None - can take with or without food 12
No clinically relevant differences in exposure based on sex, age, race, body size, or renal/hepatic function (except CYP2D6 poor metabolizers) 12.
Clinical Context
While older guidelines from 2008 discuss second-generation antidepressants broadly 9, vortioxetine represents a newer option (FDA approved 2013) with a distinct pharmacological profile. The 2023 update alert confirms vortioxetine's efficacy when switching from other antidepressants 13, supporting its use as second-line therapy after SSRI/SNRI failure, with remission rates of 32-55% in this population 7.
The recommended approach for treatment-resistant depression involves rapid up-titration to 20 mg daily by day 8, with effectiveness assessed at 8-12 weeks 7 - a more aggressive strategy than typical initial MDD treatment.